Jason Beattie

Jason Beattie

Auto-generated profile, based on publicly available information

Jason Beattie

Department of Surgery, Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA, harvard.edu

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JBJason Beattie
Jason Beattie
HRHira Rizvi
Hira Rizvi
PFPaige Fuentes
Paige Fuentes
JLJia Luo
Jia Luo
ASAdam Schoenfeld
Adam Schoenfeld
MHMatthew D Hellmann
Matthew D Hellmann
Background Pneumonitis related to immune checkpoint blockade is uncommon but can be severe, fatal or chronic. Steroids are first-line treatment, however, some patients are refractory or become resistant to steroids. Like many immune-related adverse events, little is known regarding the outcomes and optimal management of patients in whom steroids are ineffective. Methods We performed a single-center retrospective cohort study at a high-volume tertiary cancer center to evaluate the clinical course, management strategies and outcomes of patients treated for immune checkpoint pneumonitis with immune modulatory medications in addition to systemic steroids. Pharmacy records were queried for patients treated with both immune checkpoint blockade and receipt of additional immune modulators. Records were then manually reviewed to identify patients who received the additional immune modulators for immune checkpoint pneumonitis. Results From 2013 to 2020, we identified 26 patients treated for immune checkpoint pneumonitis with additional immune modulators in addition to steroids. Twelve patients (46%) were steroid-refractory and 14 (54%) were steroid-resistant. Pneumonitis severity included grade 2 (42%) or grade 3–4 (58%). Additional immune modulation consisted of tumor necrosis factor-alpha inhibitor (77%) and/or mycophenolate (23%). Durable improvement in pneumonitis following initiation of additional immune modulators occurred in 10 patients (38%), including three patients (12%) in whom pneumonitis resolved and all immunosuppressants ceased. The rate of 90-day all-cause mortality/hospice referral was 50%. At last follow-up, mortality attributable to pneumonitis was 23%. In addition to mortality from pneumonitis and cancer, 3 patients (12%) died due to infections possibly associated with immunosuppression. Conclusions Steroid-refractory or -resistant immune checkpoint pneumonitis is uncommon but associated with significant morbidity and mortality. Additional immunomodulators can yield durable improvement, attained in over one third of patients. An improved understanding of the underlying biology of immune-related pneumonitis will be crucial to guide more precise and effective treatment strategies in the future.

1 July 2021 in Lung Cancer
Verified
Journal Article
Closed access
NCNavin K. Chintala
Navin K. Chintala
DRDavid Restle
David Restle
HQHue Quach
Hue Quach
JSJasmeen Saini
Jasmeen Saini
RBRebecca Bellis
Rebecca Bellis
PAPrasad S. Adusumilli
Prasad S. Adusumilli

20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JBJason Beattie
Jason Beattie
PFPaige Fuentes
Paige Fuentes
HRHira Rizvi
Hira Rizvi
JLJia Luo
Jia Luo
ASAdam Jacob Schoenfeld
Adam Jacob Schoenfeld
MHMatthew David Hellmann
Matthew David Hellmann
3078 Background: Severe immune related adverse events (irAEs) with immune checkpoint blockade are uncommon but can be fatal. Steroids are the most common initial treatment for most non-endocrine irAEs, but some patients are or become refractory to steroids. When steroids are not effective, there is limited data to guide management strategies, particularly in the context of pneumonitis. Methods: All patients at MSK treated with immune checkpoint blockade from 2013-2020 were queried for receipt of an immunosuppressant (e.g. TNF antagonists, mycophenolate mofetil, cyclophosphamide) beyond steroids. Patient records were then manually reviewed to identify patients who received such therapy for management of immunotherapy-related pneumonitis. Results: Among 5363 patients treated with immune checkpoint blockade, 364 (6.8%) received an additional immunosuppressant for an irAE, including 28 (0.5% of all patients treated) patients treated for pneumonitis. Most of these pneumonitis events (19/28, 68%) were grade 3 or higher. Agents used included mycophenolate mofetil (7/28; 25%), TNF antagonists (23/28; 82%), and cyclophosphamide (1/28; 3.5%); more than one medication was used in 3 patients (11%). The indications were primary non-response to steroids (n = 16, 57%) and recrudescence after initial response to steroids (n = 12, 43%). At 90 days from initiation of the additional immunosuppressant, 13/28 (46%) patients were alive with improvement or resolution of pneumonitis while 15/28 (54%) had died. Survival with resolution/improvement was more common in patients treated for recrudescence vs primary non-response (67% vs 25%, p = 0.05). Conclusions: Outcomes with additional immunosuppressants in the setting of steroid-refractory immune-related pneumonitis are poor, but resolution can occur in some cases. A deeper understanding of the mechanistic underpinnings of irAEs is needed to more effectively tailor immunosuppressant therapies, particularly in severe pneumonitis events.

21 December 2021 in Journal of Bronchology & Interventional Pulmonology
Verified
Journal Article
Closed access
JBJason Beattie
Jason Beattie
DODaniel Ospina-Delgado
Daniel Ospina-Delgado
SGSidhu P. Md Gangadharan
Sidhu P. Md Gangadharan
ACAlex Chee
Alex Chee
MPMihir Parikh
Mihir Parikh
AMAdnan Majid
Adnan Majid

1 January 2026 in Case Reports in Pulmonology
Verified
Journal Article
Open access
HNHamad Nasim
Hamad Nasim
RWRobert Willim
Robert Willim
JBJason Beattie
Jason Beattie
AMAdnan Majid
Adnan Majid
MPMihir Parikh
Mihir Parikh
KSKai Swenson
Kai Swenson
Primary pulmonary lymphomas (PPLs) are rare clinical entities representing 0.5%–1% of all pulmonary neoplasms, of which mucosa‐associated lymphoid tissue (MALT) lymphoma is the most common type (80%). PPLs are traditionally considered challenging to diagnose bronchoscopically given the rarity of these entities, small sample sizes, and the ancillary testing often required to adequately differentiate them from benign intraparenchymal lymph nodes. Here, we report three cases of pulmonary MALT lymphomas. In two cases, the patients presented with pulmonary nodules and were diagnosed by robotic‐assisted bronchoscopy following prior nondiagnostic biopsy attempts. The third patient presented with distal tracheal thickening, where flexible bronchoscopy revealed a particularly rare case of MALT lymphoma with endobronchial involvement.